MedTrace Logo

Efficacy of Amantadine Treatment in COVID-19 Patients

NCT04952519 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2022-09-30

No results posted yet for this study

Summary

Demonstration of the efficacy of amantadine over placebo in the population of patients with moderate or severe COVID-19 in the initial stage of the disease treated in the hospital

Conditions

  • Patients With Moderate or Severe COVID-19

Interventions

DRUG

Amantadine

Patients are treated with high doses of amantadine.

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV

  • Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice, Poland

    collaborator UNKNOWN

  • Noblewell

    lead INDUSTRY

Principal Investigators

  • Adam Barczyk, Prof. · Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2022-03-10
Completion
2022-03-10

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04952519 on ClinicalTrials.gov